[Federal Register: February 25, 1999 (Volume 64, Number 37)]
[Notices]               
[Page 9337]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr25fe99-71]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

 
Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development.

ADDRESS: Licensing information and a copy of the U.S. patent 
application referenced below may be obtained by contacting J.R. Dixon, 
Ph.D., at the Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-
3804 (telephone 301/496-7056 ext 206; fax 301/402-0220; E-Mail: 
jd212g@NIH.GOV). A signed Confidential Disclosure Agreement is required 
to receive a copy of any patent application.

Entitled: Immunotoxins Directed Against Malignant B-Cells 
[Immunotoxins, Comprising an ONC Protein, Directed Against 
Malignant Cells]

    Inventors: Drs. Susanna M. Rybak (NCI-FCRDC), Dianne Newton (NCI-
FCRDC), and David Goldenberg (EM), DHHS Ref. No. E-157-97/0 filed 2 
March 1997, [= PCT/US98/08983 filed 1 May 1998] and 09/071,672 filed 5 
May 1998.
    This invention relates to immunotoxins, that are useful for killing 
malignant B-Cells and other malignant cells and are directed to a 
surface marker on B-Cells and the nucleic acid constructs encoding the 
immunotoxins. These reagents comprise a toxic moiety that is derived 
from a Rana pipiens protein having a ribonucleolytic activity linked to 
an antibody capable of specific binding with a chosen tumor cell. It 
has been found that these immunotoxins are up to 2,000 fold more active 
against malignant B-Cells than their human RNase counterparts or the 
toxin itself. These immunotoxins when administered in vivo against 
disseminated tumors, resulted in dramatically lower side effects. These 
highly effective, but apparently non-toxic immunotoxins directed 
against such ubiquitous diseases as B-Cell Lymphomas and Leukemias and 
other malignancies, such as neuroblastoma, present a new and exciting 
therapeutic option for patients suffering from such diseases.
    The above mentioned invention is available, including any foreign 
intellectual property rights, for licensing on an exclusive or non-
exclusive basis.

    Dated: February 16, 1999.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 99-4657 Filed 2-24-99; 8:45 am]
BILLING CODE 4140-01-M